Eli Lilly and Company Share Price

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse 01:30:13 19/06/2024 am IST 5-day change 1st Jan Change
891.5 USD +0.73% Intraday chart for Eli Lilly and Company +2.79% +52.93%
Sales 2024 * 42.98B 3,584B Sales 2025 * 52.62B 4,388B Capitalization 803B 66,938B
Net income 2024 * 11.93B 995B Net income 2025 * 16.55B 1,380B EV / Sales 2024 * 19.1 x
Net Debt 2024 * 18.06B 1,506B Net Debt 2025 * 15B 1,251B EV / Sales 2025 * 15.5 x
P/E ratio 2024 *
66.7 x
P/E ratio 2025 *
48 x
Employees 43,000
Yield 2024 *
0.58%
Yield 2025 *
0.67%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.73%
1 week+2.79%
Current month+8.67%
1 month+15.77%
3 months+15.36%
6 months+53.75%
Current year+52.93%
More quotes
1 week
876.00
Extreme 876
894.87
1 month
788.25
Extreme 788.25
894.87
Current year
579.05
Extreme 579.05
894.87
1 year
434.34
Extreme 434.34
894.87
3 years
217.00
Extreme 217
894.87
5 years
101.36
Extreme 101.36
894.87
10 years
60.14
Extreme 60.14
894.87
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01/96/01
President - -
Chief Tech/Sci/R&D Officer - 16/23/16
Members of the board TitleAgeSince
Director/Board Member 63 25/21/25
Director/Board Member 68 01/09/01
Director/Board Member 63 01/05/01
More insiders
Date Price Change Volume
18/24/18 891.5 +0.73% 2,437,038
17/24/17 885 +0.75% 2,532,240
14/24/14 878.4 -0.55% 2,022,270
13/24/13 883.3 +1.85% 2,243,419
12/24/12 867.3 +0.17% 2,594,601

Delayed Quote Nyse, June 19, 2024 at 01:30 am IST

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5 USD
Average target price
855.4 USD
Spread / Average Target
-4.05%
Consensus